Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity
Wenjie Yin, Dorothée Duluc, HyeMee Joo, et al.
Cancer Immunology Research (2016) Vol. 4, Iss. 10, pp. 823-834
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek, Francisco J. Cueto, Adriana M. Mujal, et al.
Nature reviews. Immunology (2019) Vol. 20, Iss. 1, pp. 7-24
Closed Access | Times Cited: 2016
Cross-priming in cancer immunology and immunotherapy
Carlos Luri‐Rey, Álvaro Teijeira, Stefanie K. Wculek, et al.
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 4
Activities of stromal and immune cells in HPV-related cancers
Marconi Rêgo Barros Júnior, Cristiane Moutinho Lagos de Melo, Maria Luiza Carneiro Moura Gonçalve Barros, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 70
Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy
Katherine M. Audsley, Alison M. McDonnell, Jason Waithman
Cells (2020) Vol. 9, Iss. 3, pp. 565-565
Open Access | Times Cited: 42
A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
Yadira Pastor, Olivier Reynard, Mathieu Iampietro, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101467-101467
Open Access | Times Cited: 6
Next generation CD40 agonists for cancer immunotherapy
Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 351-363
Open Access | Times Cited: 5
<p>Cervical Cancer: Emerging Immune Landscape and Treatment</p>
Luopei Guo, Keqin Hua
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 8037-8047
Open Access | Times Cited: 39
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 12, pp. 1635-1646
Open Access | Times Cited: 25
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
Karin Hägerbrand, Laura Varas, Adnan Deronic, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 11, pp. e005018-e005018
Open Access | Times Cited: 17
Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva
JKW Yap, Danielle O’Neill, Sangeetha Nagenthiran, et al.
BJOG An International Journal of Obstetrics & Gynaecology (2017) Vol. 124, Iss. 6, pp. 946-954
Open Access | Times Cited: 33
Refining the DC-targeting vaccination for preventing emerging infectious diseases
Yadira Pastor, Nour Ghazzaui, Adele Hammoudi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)
Yves Lévy, Christiane Moog, Aurélie Wiedemann, et al.
EClinicalMedicine (2024) Vol. 77, pp. 102845-102845
Open Access | Times Cited: 3
Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines
Valentina Ceglia, Sandra Zurawski, Monica Montes, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 13
Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors
Zacharias Wijfjes, Floris J. van Dalen, Camille M. Le Gall, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 10, pp. 4826-4847
Open Access | Times Cited: 7
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
Adnan Deronic, Anneli Nilsson, Mia Thagesson, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 12, pp. 3629-3642
Open Access | Times Cited: 16
Novel canonical and non-canonical viral antigens extend current targets for immunotherapy of HPV-driven cervical cancer
Peng Xu, Isaac Woodhouse, Gemma Hancock, et al.
iScience (2023) Vol. 26, Iss. 3, pp. 106101-106101
Open Access | Times Cited: 6
Dendritic Cell Targeting Vaccine for HPV-Associated Cancer
Wenjie Yin, Dorothée Duluc, HyeMee Joo, et al.
Cancer Cell & Microenvironment (2017)
Open Access | Times Cited: 17
Identification of key biomarkers and related immune cell infiltration in cervical cancer tissue based on bioinformatics analysis
Guang Zhu, Zhihui Xiong, Wenzeng Chen, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates
Anne-Laure Flamar, Henri Bonnabau, Sandra Zurawski, et al.
PLoS ONE (2018) Vol. 13, Iss. 11, pp. e0207794-e0207794
Open Access | Times Cited: 12
Vaccination with human papillomavirus-18 E1 protein plus α-galactosyl-ceramide induces CD8+ cytotoxic response and impairs the growth of E1-expressing tumors
Alfredo Amador-Molina, Cesar Trejo-Moreno, Dámaris P. Romero‐Rodríguez, et al.
Vaccine (2019) Vol. 37, Iss. 9, pp. 1219-1228
Open Access | Times Cited: 11
Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties
Valentina Ceglia, Sandra Zurawski, Monica Montes, et al.
The Journal of Immunology (2021) Vol. 207, Iss. 8, pp. 2060-2076
Open Access | Times Cited: 10
Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer
Jie Chang, Shimin Quan, Sijuan Tian, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 6
Open Access | Times Cited: 1
Targeting interferon-alpha to dendritic cells enhances a CD8 + T cell response to a human CD40-targeted cancer vaccine
John Graham, Pierre Authié, Karolina Palucka, et al.
Vaccine (2017) Vol. 35, Iss. 35, pp. 4532-4539
Closed Access | Times Cited: 10
Human papillomavirus E7 oncoprotein expression by keratinocytes alters the cytotoxic mechanisms used by CD8 T cells
Purnima Bhat, Anne‐Sophie Bergot, Nigel J. Waterhouse, et al.
Oncotarget (2017) Vol. 9, Iss. 5, pp. 6015-6027
Open Access | Times Cited: 10
Targeting human langerin promotes HIV-1 specific humoral immune responses
Jérôme Kervevan, Aurélie Bouteau, Juliane S. Lanza, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 7, pp. e1009749-e1009749
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top